6660 — AIM Vaccine Share News
0.000.00%
Last trade - 00:00- HK$1.93bn
- HK$3.99bn
- CNY1.17bn
Brief: AIM Vaccine Says MRNA Respiratory Syncytial Virus Vaccine Obtained Approval
Brief: Aim Vaccine Submits Application For Clinical Trials For Absorbed Tetanus Vaccine
Brief: Aim Vaccine Posts HY Loss Attributable RMB139.3 Million
Brief: AIM Vaccine Says Jie Zhou, Xin Zhou Re-Designated To Executive Directors
Brief: AIM Vaccine Says Pre-Applications For Clinical Trials Submitted To US FDA
Brief: AIM Vaccine Posts H1 Gross Profit RMB 388.3 Million
Brief: Aim Vaccine Says Further Increase In Shareholding Of H Shares By Controlling Shareholder
Brief: AIM Vaccine Says FY Revenue RMB1.19 Billion
Brief: Aim Vaccine Says Phase 3 Clinical Trials For 13-Valent Pneumonia Conjugate Vaccine Completed
Brief: Aim Vaccine Sees FY Unaudited Net Loss Ranging From RMB1.81 Billion To RMB1.99 Billion
Brief: Aim Vaccine Says Xin Zhou Elected As Executive Vice-Chairman
Brief: Aim Vaccine Says Further Increase In Shareholding Of H Shares By Controlling Shareholder
Brief: AIM Vaccine Co Announces Increase In Shareholding Of H Shares By Controlling Shareholder
Brief: Aim Vaccine Says Further Increase In Shareholding Of H Shares By Controlling Shareholder
Brief: Aim Vaccine Says From Dec 1 to Dec 6 Controlling Shareholder Acquired Additional H Shares
Brief: Aim Vaccine Says Further Increase In Shareholding Of H Shares By Controlling Shareholder
Brief: Aim Vaccine Co Announces Increase In Shareholding Of H Shares By Controlling Shareholder
China's AIM Vaccine surges on share buyback plan
Brief: Aim Vaccine Intends To Repurchase H Shares On Market